DOCSLIB.ORG

MATTHEW J. MIMIAGA Updated: September 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MATTHEW J. MIMIAGA Updated: September 2021 Mimiaga, p.1 MATTHEW J. MIMIAGA Updated: September 2021 Office Address University of California, Los Angeles Fielding School of Public Health Department of Epidemiology BOX 951772, 71-267 CHS Los Angeles, CA 90095-1772 [email protected] Appointments Professor (tenured), Department of Epidemiology, UCLA Fielding School of Public Health; and Department of Psychiatry and Biobehavioral Sciences, UCLA David Geffen School of Medicine Director, UCLA Center for LGBTQ Advocacy, Research and Health (C-LARAH) Senior Research Scientist, Division of Epidemiology & Global Health Research, The Fenway Institute, Fenway Health Place of Birth Los Angeles, CA Education 2001 B.S. Psychology and Biological Cal Poly, San Luis Sciences Obispo, CA 2003 M.P.H. Dual Concentration: Epidemiology Boston University, and Behavioral Sciences School of Public Health, Boston, MA 2007 Sc.D. Major Fields: Psychiatric and Harvard University, Infectious Disease Epidemiology T.H. Chan School of Public Health, Boston, Minor: Biostatistics MA 2017 A.M. Public Health, Ad Eundem Brown University, Providence, RI Pre-Doctoral 09/1999- Post- HIV/AIDS Research UCSF Center for Internship 08/2000 Baccalaureate AIDS Prevention Research Studies (CAPS) / Training Alliance Health Internship Project (AHP), San Francisco, CA Post-Doctoral 05/2007- Post-Doctoral Behavioral Medicine Harvard Medical Fellowship 04/2008 Research (Senior Research Mentors: School, Boston, MA Training Steven A. Safren, PhD; Fellowship Kenneth H. Mayer, MD) Mimiaga, p.2 Faculty Academic Appointments HARVARD UNIVERSITY 2007 Post-Doctoral Fellow in Psychiatry Harvard Medical School, Boston, MA (Behavioral Medicine) 2008-2009 Instructor in Psychiatry Harvard Medical School, Boston, MA 2008-2009 Instructor in Epidemiology Harvard T.H. Chan School of Public Health, Boston, MA 2010-2012 Assistant Professor of Psychiatry Harvard Medical School, Boston, MA 2010-2012 Assistant Professor of Epidemiology Harvard T.H. Chan School of Public Health, Boston, MA 2013-2014 Associate Professor of Psychiatry Harvard Medical School, Boston, MA 2013-2014 Associate Professor of Epidemiology Harvard T.H. Chan School of Public Health, Boston, MA 2015-2017 Adjunct Professor of Epidemiology Harvard T.H. Chan School of Public Health, Boston, MA BROWN UNIVERSITY 2015-2020 Professor of Epidemiology (tenured) Brown School of Public Health, Providence, RI 2015-2020 Professor of Behavioral & Social Sciences Brown School of Public Health, (tenured) Providence, RI 2015-2020 Professor of Psychiatry & Human Behavior Brown (Alpert) Medical School, (tenured) Providence, RI 2020-present Adjunct Professor of Behavioral & Social Brown School of Public Health, Sciences and Epidemiology Providence, RI UNIVERSITY OF CALIFORNIA, LOS ANGELES 2020-present Professor of Epidemiology (tenured) UCLA, Fielding School of Public Health, Los Angeles, CA 2020-present Professor of Psychiatry and Biobehavioral UCLA, David Geffen School of Sciences (tenured; joint appointment) Medicine, Los Angeles, CA Hospital or Affiliated Institution Appointments 2001-present Research Associate (2001) The Fenway Institute, Fenway Health Senior Research Associate (2002) (Harvard Medical School affiliate), Epidemiology Projects Manager (2003- Boston, MA 2004) Epidemiology Projects Director (2005- 2006 Research Scientist (2007-2010) Director, Division of Epidemiology and Global Health Research (2007-2019) Senior Research Scientist (2011-present) Mimiaga, p.3 2007-2008 Fellow in Behavioral Medicine, Department Massachusetts General Hospital, of Psychiatry Boston, MA 2008-2010 Assistant faculty in Research Massachusetts General Hospital, Boston, MA 2010-2015 Associate faculty in Research Massachusetts General Hospital, Boston, MA 2016-2017 Visiting Scientist, Center for Health & Harvard University, Boston, MA Human Rights Leadership and Senior Administrative Academic Positions 2007-2020 Director, Division of Epidemiology and The Fenway Institute, Fenway Health Global Health Research 2015-2018 Director, Center for Health Equity Research Brown University, Providence, RI (previously the Institute for Community Health Promotion) 2020- present Inaugural Director, Center for LGBTQ UCLA, Los Angeles, CA Advocacy, Research & Health Other Professional / Volunteer Positions 1996-1998 Program Coordinator AIDS Support Network (Sexual Health Program), San Luis Obispo, CA 1997-1998 Student Body President College of Science and Mathematics, Elected to the office through student-run Cal Poly, San Luis Obispo, CA elections; presided over a student body of 2,700 and a 15-member committee. 1998-1999 Director of Weekend Program United Way / Friends Outside, San For adolescents with incarcerated parent(s) Luis Obispo, CA 1999-2000 Substance Abuse Residential Treatment Walden House, San Francisco, CA Counselor 1999-2000 HIV Support Group Facilitator UCSF/CAPS, San Francisco, CA 1999-2000 HIV Counseling and Testing Volunteer UCSF/CAPS/AIDS Health Project, San Francisco, CA 2000-2001 HIV Counseling and Testing Volunteer Department of Public Health, San Luis Obispo County, CA 2007-2011 Director of Research, Board of Directors Hope Web Design, Denver, CO 2012-2017 Director of Health Services and Research, Project Weber/RENEW, Providence, RI Board of Directors 2017-present Emeritus Member, Board of Directors Project Weber/RENEW, Providence, RI Mimiaga, p.4 2014-present Alumni Ambassador Volunteer Harvard International Alumni Ambassador Program, Boston, MA 2018-present Alumni Learning and Career Linkages Harvard T.H. Chan School of Public Committee Volunteer Health Alumni Association 2020-2021 COVID-19 Testing Volunteer Rhode Island Disaster Medical Assistance Team | Rhode Island Medical Reserve Corps Leadership Roles on Committees / Academic Committee Service Local (at time of participation) 2007-2015 Interdisciplinary Research Committee Harvard Medical School, Department of Psychiatry 2008-2015 Member of Outcomes Research Program Harvard Division of AIDS / Partners AIDS Research Center / CFAR 2008-2015 Member of International AIDS Program Harvard Division of AIDS / Partners AIDS Research Center / Center for AIDS Research 2008, 2010, 2013, Faculty Search Committee Harvard Medical School, Behavioral 2014, 2015 Medicine, Department of Psychiatry 2008-2015 Behavioral Medicine and Adult Cognitive Harvard Medical School, Behavioral Behavioral Therapy Clinical Internship in Medicine, Department of Psychiatry Psychology Seminar Series Committee 2009-2015 Psychiatry Department Research Massachusetts General Hospital, Committee on Global Health Department of Psychiatry 2009, 2010, 2011, Admissions Review Committee: Infectious Harvard T.H. Chan School of Public 2012, 2013, 2014, Disease/HIV Epidemiology Track Health, Department of Epidemiology 2015 2011-2015 Scientific Committee for Epidemiology Harvard T.H. Chan School of Public Research Seminar Series Health, Department of Epidemiology 2012, 2014, 2015 Faculty Search Committee Harvard T.H. Chan School of Public Health, Department of Epidemiology 2012-2015 Psychiatry Steering Committee Massachusetts General Hospital, Department of Psychiatry 2013-2015 CFAR Social and Behavioral Sciences Harvard Center for AIDS Research Leadership Core (one of four members) 2014-2015 Appointments and Promotions Committee Harvard Medical School, Department of Psychiatry 2015- 2019 Behavioral and Social Sciences Executive Brown School of Public Health Committee Mimiaga, p.5 2015- 2017 M.P.H. Admissions Review Committee Brown School of Public Health 2015- 2020 Public Health Curriculum Committee Brown School of Public Health 2016-2020 CFAR Executive Committee The Providence/Boston Center for AIDS Research 2016, 2018 School of Public Health Research Day Brown School of Public Health Abstract Reviewer 2016 School of Public Health Research Day Brown School of Public Health Scientific Poster Session Judge 2016 Faculty Search Committee Brown School of Public Health, Department of Behavioral and Social Health Sciences 2016, 2017, 2018, Fellowship Advisory Committee and Faculty Brown University 2019, 2020 Mentor, Initiative to Maximize Student Development (IMSD) 2015-2018 Faculty Executive Committee—University Brown University Wide (elected to the Committee by voting members of the faculty for a three-year term) 2015, 2016, 2017, Epidemiology Doctoral Admissions Brown School of Public Health, 2018, 2019 Committee Department of Epidemiology 2016, 2017, 2018, Chair, Faculty Promotions and Brown School of Public Health, 2019 Appointments Committee Departments of Epidemiology and Behavioral & Social Sciences 2017-2019 Epidemiology Senior Advisory Committee Brown School of Public Health, Department of Epidemiology 2015-2018 Director, Center for Health Equity Research Brown University (previously the Institute for Community Health Promotion) 2018 School of Public Health Research Day Brown School of Public Health Scientific Poster Session Judge 2015, 2016, 2017, Health Policy Mentor for Adedotun The Health Policy Research Scholars 2018, 2019 Ogunbajo, PhD, MPH, ScM Program, Robert Wood Johnson Foundation 2016, 2017, 2018 Health Policy Mentor for Arjee Restar, PhD, The Health Policy Research Scholars MPH Program, Robert Wood Johnson Foundation 2019-present Strategic Planning Working Group The Fenway Institute 2018-2019 University-Wide Committee on Grievance Brown University 2020 Committee for Medical Faculty Brown (Alpert) Medical School Appointments (CMFA) Mimiaga, p.6 2020-present Epidemiology Doctoral Admissions UCLA Fielding School of Public Health Committee 2021- Scientific Steering Committee
Load more

Recommended publications
  • The CAB Bulletin HIV Vaccines and the Community
    The CAB Bulletin HIV Vaccines and the Community Planning for PrEP My First Time By Genevieve Meyer, HVTN Community Education Unit By Dino Martino, On November 23rd, 2010, the results of the iPrEx study were released. The Orlando, FL CAB member. 2,499-person study demonstrated that a daily dose of oral Truvada®, (a With nervous excitement I accepted combination of two antiretroviral medications, emtricitabine and tenofovir) could the offer to attend my first HVTN reduce new infections of HIV in gay men, transwomen and other men who have conference. As a member of the sex with men (MSM) by an average of 43.8%. The HVTN salutes the sponsors, newly formed CAB in Orlando, this study team, and volunteers in the 11 sites throughout Brazil, Ecuador, Peru, South Africa, Thailand and the United States who contributed to this study’s success. was another “first time” opportu- nity in a series of events that I have The results of the iPrEx study have added increased vigor to the HVTN’s search had the pleasure to be a part of in for a safe and effective HIV vaccine. One central question being asked at the HVTN support of the work of the HVTN. right now is what these results mean for participants in HVTN 505, a study which is also enrolling MSM and transwomen who are at risk of contracting HIV. As a pharmacist for nearly two de- cades, scientific conferences are not The Network has set up a working group to solicit feedback from community new to me; still, each one brings stakeholders about possible changes to HVTN 505 based on the iPrEx results.
    [Show full text]
  • Antibody Fc Effector Functions and Igg3 Associate with Decreased HIV-1 Risk
    RESEARCH ARTICLE The Journal of Clinical Investigation Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk Scott D. Neidich,1 Youyi Fong,2,3,4 Shuying S. Li,2,3 Daniel E. Geraghty,5 Brian D. Williamson,4 William Chad Young,2 Derrick Goodman,1 Kelly E. Seaton,1 Xiaoying Shen,1 Sheetal Sawant,1 Lu Zhang,1 Allan C. deCamp,2 Bryan S. Blette,6 Mengshu Shao,2 Nicole L. Yates,1 Frederick Feely,1 Chul-Woo Pyo,3 Guido Ferrari,1,7,8 HVTN 505 Team,9 Ian Frank,10 Shelly T. Karuna,3 Edith M. Swann,11 John R. Mascola,12 Barney S. Graham,12 Scott M. Hammer,13 Magdalena E. Sobieszczyk,13 Lawrence Corey,3 Holly E. Janes,2,3,4 M. Juliana McElrath,3 Raphael Gottardo,2,3 Peter B. Gilbert,2,3,4 and Georgia D. Tomaras1,7,8,14 1Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA. 2Statistical Center for HIV/AIDS Research and Prevention, 3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4Department of Biostatistics, University of Washington, Seattle, Washington, USA. 5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 6Department of Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA. 7Department of Surgery and 8Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA. 9The HVTN 505 Team is detailed in the Supplemental Acknowledgments. 10Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia Pennsylvania, USA. 11Division of AIDS and 12Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
    [Show full text]
  • Unaids Programme Coordinating Board
    UNAIDS PROGRAMME COORDINATING BOARD UNAIDS/PCB(33)/13.CRP5 Issue date: 10 December 2013 THIRTY-THIRD MEETING Date: 17-19 December 2013 Venue: Executive Board Room, WHO, Geneva Agenda item 9 PCB Submissions on Thematic Segment - HIV, Adolescents and Youth 1 Disclaimer: This compilation of submissions is for information only. With the exception of minor corrections to grammar and spelling, the submissions within this document are presented as they were submitted, and do not, implied or otherwise, express or suggest endorsement, a relationship with or support by UNAIDS and its mandate and/or any of its co-sponsors, Member States and civil society. The content of submissions has not been independently verified. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of UNAIDS concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Nor does the content of the submissions necessarily represent the views of Member States, civil society, the UNAIDS Secretariat or the UNAIDS Cosponsors. The published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall UNAIDS be liable for damages arising from its use. UNAIDS expressly disclaims any responsibility for inadvertent offensive or insensitive, perceived or actual, language. 2 Table of Contents Introduction…………………………………………………….……………………….……………. Page 9 I. Africa 104 submissions…………………………………………………………………………. Page 9 – 149 1. Algeria: Establishment of Three Animated Prevention Clubs against HIV in the Youth Community 2.
    [Show full text]
  • Safety and Immunogenicity of a Recombinant Adenovirus Serotype
    C S & lini ID ca A l f R o e l s Fuchs et al., J AIDS Clin Res 2015, 6:5 a e n a r r u c o h J AIDS & Clinical http://dx.doi.org/10.4172/2155-6113.1000461 ISSN: 2155-6113 Research Research Article Open Access Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals Jonathan D Fuchs1,2,*, Pierre-Alexandre Bart3, Nicole Frahm4, Cecilia Morgan4, Peter B Gilbert4, Nidhi Kochar4, Stephen C DeRosa4, Georgia D Tomaras5, Theresa M Wagner1, Lindsey R Baden6, Beryl A Koblin7, Nadine G Rouphael8, Spyros A Kalams9, Michael C Keefer10, Paul A Goepfert11, Magdalena E Sobieszczyk12, Kenneth H Mayer13, Edith Swann14, Hua-Xin Liao5, Barton F Haynes5, Barney S Graham15 and M Juliana McElrath4 for the NIAID HIV Vaccine Trials Network 1Population Health Division, San Francisco Department of Public Health, San Francisco, CA, USA 2Department of Medicine, University of California, San Francisco, San Francisco, USA 3Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland 4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 5Human Vaccine Institute, Duke University, Durham, NC, USA 6Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USA 7Laboratory of Infectious Disease Prevention, New York Blood Center, New York, NY, USA 8The Hope Clinic, Division of Infectious Diseases, Emory University, Atlanta, GA, USA 9Infectious Diseases Division, Vanderbilt University School of Medicine, Nashville,
    [Show full text]
  • Program Book
    Program Book Page 1 Visit BD at Booth 105 BD MAX™ Vaginal Panel One clinician- or patient-collected vaginal swab provides results for the three most common causes of vaginitis – bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginalis (TV)1. BD MAX Vaginal Panel detects DNA from In addition, BD MAX Vaginal Panel utilizes the the following BV markers: CDC-recommended diagnostic technology for T. vaginalis detection2 and provides three results for microorganisms responsible for Lactobacillus spp. yeast infections: G. vaginalis • group, including C. albicans, C. A. vaginae Candida L. jensenii parapsilosis, C. tropicalis, and C. dubliniensis L. crispatus BVAB-2 Megasphaera-1 • Differentiates fungal species – C. glabrata Anaerobic spp. and C. krusei – associated with antimicrobial resistance3. The BD MAX™ Women’s Health and STI portfolio is focused on providing accurate, reliable results that enable clinicians and labs to elevate patient care. • BD MAX™ Vaginal Panel • BD MAX™ CT/GC/TV • BD MAX™ GBS Reference 1. BD MAX Vaginal Panel Package Insert 2. CDC (2015, June). MMWR Sexually Transmitted Diseases Treatment Guidelines, 2015. Mills, BB (2017) Vaginitis: Beyond the Basics. Obstet Gynecol Clin North Am. 44(2):159-177. 3. Gaydos CA (2017) Clinical Validation of a Test for the Diagnosis of Vaginitis. Obstet Gynecol. 130(1):181-189. BD, the BD Logo and the BD MAX are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved. April 2019. Page 2 MAX MVP AD_5_5x8_5_GreenJournalAd_April.indd
    [Show full text]
  • (Sexpro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States
    Title: Development and Validation of the Personalized Sexual Health Promotion (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States. Authors Title Email Site Hyman Scott [email protected] Bridge HIV, San Francisco Department of (corresponding) Public Health, San Francisco, California Eric Vittinghoff [email protected] University of California, San Francisco, San Francisco, CA Risha Irvin [email protected] John’s Hopkins School of Medicine, Baltimore, Maryland Albert Liu [email protected] Bridge HIV, San Francisco Department of Public Health, San Francisco, CA LaRon Nelson [email protected] University of Rochester. Rochester, New er.edu York Carlos Del Rio [email protected] Emory University, Atlanta, Georgia Manya Magnus [email protected] George Washington University, Washington, District of Columbia Sharon [email protected] Columbia University, New York, New Mannheimer York Sheldon Fields [email protected] Charles Drew School of Medicine, Los Angeles, California Irene Kuo [email protected] George Washington University, Washington, District of Columbia Steve Shoptow [email protected] University of California, Los Angeles, California Beatrice [email protected] Instituto de Pesquisa Clinica Evandro Grinsztejn Chagas (IPEC), Rio de Janeiro, Brazil Jorge Sanchez [email protected] Asociacion Civil Impacta Salud y Educacion, Lima, Peru Steven [email protected] Fred Hutchinson Cancer Research Center, Wakefield Seattle, Washington Jonathan Fuchs [email protected]
    [Show full text]
  • Advancing Toward HIV-1 Vaccine Efficacy Through the Intersections of Immune Correlates
    Vaccines 2014, 2, 15-35; doi:10.3390/vaccines2010015 OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Review Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates Georgia D. Tomaras 1,* and Barton F. Haynes 2 1. Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke Human Vaccine Institute, Durham, NC 27710, USA 2. Departments of Medicine and Immunology, Duke Human Vaccine Institute, Durham, NC 27710, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-919-681-5598; Fax: +1-919-684-5230. Received: 29 October 2013; in revised form: 29 October 2013 / Accepted: 9 December 2013 / Published: 27 December 2013 Abstract: Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine clinical trials have provided hypotheses regarding the mechanisms of induction of protective immunity to HIV-1. To date, there have been six HIV-1 vaccine efficacy trials (VAX003, Vaxgen, Inc., San Francisco, CA, USA), VAX004 (Vaxgen, Inc.), HIV-1 Vaccine Trials Network (HVTN) 502 (Step), HVTN 503 (Phambili), RV144 (sponsored by the U.S. Military HIV Research Program, MHRP) and HVTN 505). Cellular, humoral, host genetic and virus sieve analyses of these human clinical trials each can provide information that may point to potentially protective mechanisms for vaccine-induced immunity. Critical to staying on the path toward development of an efficacious vaccine is utilizing information from previous human and non-human primate studies in concert with new discoveries of basic HIV-1 host-virus interactions. One way that past discoveries from correlate analyses can lead to novel inventions or new pathways toward vaccine efficacy is to examine the intersections where different components of the correlate analyses overlap (e.g., virus sieve analysis combined with humoral correlates) that can point to mechanistic hypotheses.
    [Show full text]
  • The CAB Bulletin HIV Vaccines and the Community in This Issue: S
    The CAB Bulletin HIV Vaccines and the Community In this Issue: S. Africa CAB Retreat 2 CROI, GCAB Elections 3 Full Group Meeting 4-5 Honors & Awards 6-7 Calls & Announcements 8 From Unique Paths, Hope Takes Action— The Community Education Unit Reflections on the U.S./Swiss CAB Retreat Welcomes Niles Eaton By Reese Aaron Isbell, San Francisco CAB member Those who attended the Full Group Editor’s note on the CAB Retreats: From April 9-11, 2010 the CEU conducted a Meeting were introduced to the new U.S./Swiss CAB Retreat in Seattle, Washington. It was similar in format to the manager of the HVTN Community South African CAB retreat (see article by Siyabonga Nzimande in this issue): a Education Unit (CEU), Niles Eaton. train-the-trainer approach where CAB members worked with staff from the CEU to Niles may be new to the CEU but he present on topics such as an Introduction to Vaccinology, Introduction to Research is certainly not new to community Ethics, How to Read a Protocol, Vaccine-Induced Seropositivity, and many more. education or to the HVTN. Niles has Originally scheduled for June, 2010, the Latin American and Caribbean CAB spent the last seven years as a Clinical Retreat will take place in late Trials Manager and is incredibly 2010 or early 2011. “We all had two important knowledgeable about site operations We arrived separately and things in common: we were and structures. we ranged in age, race, Prior to joining creed and color. We were volunteers, and we were the HVTN, Niles gay, bi, straight, single, part of a world-wide effort to spent seven married (legally and eradicate HIV/AIDS.” years as a study one-day-soon-to-be).
    [Show full text]
  • HVTN CAB Bulletin HIV Vaccines and the Community
    HVTN CAB Bulletin HIV Vaccines and the Community In this Issue: Cape Town CAB Member Gets Published 2 HVAD Around the World 3 HVTN Conference Highlights 4 Welcome Jim Maynard! The Global CAB Welcomes David The Community Galetta as New Co-Chair Education Unit By Carrie Schonwald, Community Education Unit welcomed Jim Maynard as the new Associate Director We would like to announce the election of for Community Reverend David Galetta as International Development GCAB Co-Chair. David is currently the and Recruitment CAB Chairperson of the Desmond Tutu (overseeing both HIV Foundation in Cape Town, South Jim Maynard, Associ- ate Director for Com- Community Education Africa, where he has been a CAB member munity Development and Communications) since 2004. Rev. Galetta graduated with a & Recruitment. on May 16. Prior to the Post Graduate Diploma in International HVTN, Jim spent over Research Ethics from the University of Cape David Galetta, new international GCAB 12 years at the Fenway Institute (part Town in 2009 and serves on their Human Co-Chair. of Fenway Health) where he served as Sciences Research Ethics Committee as the Associate Director for Community …continues on page 7 Engagement. Jim brings a wealth of knowledge and experience gained during his years working with HVTN trials HVTN 505 Expands in Size and Scope as well as the HIV Prevention Trials Network (HPTN), the Microbicide Trials By Rick Church, Rich Trevino, Coco Alinsug, Jason Roberts (Community Network (MTN) and the Adolescent Trials members of the HVTN 505 protocol team) and Gail Broder, HVTN Community Network (ATN). His team leadership, Education Unit site perspective, depth of experience, and relentlessly positive energy will be a welcome addition the Core team.
    [Show full text]
  • Ongoing and Planned Trials of Preventive Hiv/Aids Vaccines (May 2012)
    ONGOING AND PLANNED TRIALS OF PREVENTIVE HIV/AIDS VACCINES (MAY 2012) Vaccine Sponsor/Funder/ Number of Status / Expected Trial 1 Phase Start Date Vaccine(s) 3 Trial Site 2 Clade abbreviation 3 Developer 2 Participants Completion Phase IIb (safety and efficacy) US (Nashville, TN; Birmingham, AL; Los Angeles, CA; San Francisco, CA; Denver, CO; Orlando, FL; Atlanta, VRC-HIVDNA016-00-VP; GA; Chicago, IL; DNA VRC-HIVADV014-00-VP Bethesda, MD; Boston, Ongoing / Expected HVTN 505 Phase IIb June 2009 DAIDS, NIAID, VRC 2,200 A, B, C Ad5 Prime: VRC-HIVDNA016- MA; New York, NY; 2013 00-VP Rochester, NY; Cleveland, OH; Philadelphia, PA; Dallas, TX; Houston, TX; Annandale, VA; Seattle, WA) Phase II (safety, adherence, acceptability, feasibility) ANRS 149 September DNA GTU-MultiHIV B DNA and Planned / Expected Phase II ANRS France (Créteil) 105 B LIGHT 2012 Lipopeptide LIPO-5 vaccines December 2014 ALVAC-HIV (vCP1521) U.S. Army Medical Canarypox Priming With VaxGen RV 305 Phase II March 2012 Research and Thailand (Chon Buri) 162 Ongoing / June 2013 gp120 B/E (AIDSVAX B/E) gp120 Materiel Command Boosting JS7 plasmid DNA and MVA62B vaccine Peru (Lima), US Ongoing, fully enrolled administered as (1) DNA January DNA DAIDS, GeoVax Labs (Birmingham, AL; San / August 2012, long- HVTN 205 Phase IIa at months 0 and 2 and 299 B 2009 Inc. Francisco, CA; New York, term follow-up Aug MVA MVA at months 4 and 6 NY; Seattle, WA) 2014 or (2) MVA at months 0, 2 and 6 Phase I/II and Ib (safety, adherence, acceptability, feasibility) January Modified Vaccinia Karolinska
    [Show full text]
  • HIV and AIDS in Georgia: a Socio-Cultural Approach
    HIV and AIDS in Georgia: A Socio-Cultural Approach The views and opinions expressed in this publication are those of the authors, and do not necessarily represent the views and official positions of UNESCO or of the Flemish government. The designations employed and the presentation of material throughout this review do not imply the expression of any opinion whatsoever on the part of UNESCO or the Flemish government concerning the legal status of any country, territory, city or area or its authorities, or concerning its frontiers or boundaries. This project has been supported by the Flemish government. Published by: Culture and Development Section Division of Cultural Policies and Intercultural Dialogue UNESCO 1, rue Miollis, 75015 Paris, FRANCE e-mail : [email protected] web site : www.unesco.org/culture/aids Project Coordination: Helena Drobná and Christoforos Mallouris Cover design and Typesetting: Gega Paksashvili Project Coordination UNESCO: CLT/CPD/CAD - Helena Drobna, Christoforos Mallouris Project Coordination Georgia: Foundation of Georgian Arts and Culture – Maka Dvalishvili Printed by “O.S.Design” UNESCO Number: CLT/CPD/CAD-05/4D © UNESCO 2005 CONTENTS Pages Forewords 4 Preface 6 Acknowledgements 8 List of acronyms 9 Map of Georgia 10 Part I. HIV and AIDS overview in Georgia Introduction 11 I.1 HIV epidemiology in Georgia 12 I.2 Surveillance 12 I.3 Some characteristics of the Georgian culture 15 I.4 Drug use in Georgia 16 I.4.1 Drug use and related risky behaviour 16 I.4.2 Risk factors for HIV among IDU population 17
    [Show full text]
  • Intentions to Use Pre-‐Exposure Prophylaxis Among Current Phase
    Intentions to use pre-exposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants Jonathan D. Fuchs, MD, MPH,1,2 Magdalena E. Sobieszczyk, MD, MPH,3 Tamra Madenwald, MA, MPH,4 Doug Grove,5 Shelly T. Karuna, MD,4 Michele Andrasik, PhD,4 Adam Sherwat, MD,6 Gail Broder,4 Kenneth Mayer, MD,7 Beryl Koblin, PhD,8 and Scott Hammer, MD3 ; HVTN 505 Protocol Team 1San Francisco Department of Public Health 2Department of Medicine, University of California, San Francisco 3Dept. of Medicine, Division of Infectious Diseases, Columbia University College of Physicians and Surgeons 4HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center 5Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center 6National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 7 Fenway Health and the Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School 8Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center Correspondence and request for reprints: Jonathan Fuchs, MD, MPH, San Francisco Department of Public Health, 25 Van Ness Ave. Suite 100, San Francisco, CA 94102, Email: tel. (415) 437-7409, fax (415) 431-7029; email: [email protected] Preliminary analyses were presented at AIDS Vaccine 2011, Bangkok, Thailand Conflicts of Interest and Source of Funding: The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases (AI068614AI068635) which supports TM, DG, SK, MA, and GB. JF is supported under a Division of AIDS CTU award (UO1AI069496); MS and SH are supported under CTU and CTSA awards (UO1AI69470, UL1RR024156); KM is supported under CTU awards (UM1AI069480-05 and UO1AI069412) and unrestricted research grant support from Gilead Sciences, Inc.
    [Show full text]